What's behind Hims & Hers's latest stock pullback?

Traders Union
All News
Stocks
Hims & hers slides 3.08% today

Highlights

Hims & Hers expanded internationally with branded GLP-1 weight-loss and men’s health treatments in Australia, driving 21% annual growth in subscriptions and monthly revenue per subscriber.
The company projects international growth will help revenue but expects a near-term negative impact on gross profit margins.
Shares of Hims & Hers closed at $28.67, near the day’s low, with technical indicators showing continued selling pressure and an expected five-day range of $26.96 to $30.38.

Subscription growth as international offerings widen but margin pressure emerges

Hims & Hers expanded internationally by introducing branded GLP-1 weight-loss medications and additional treatments for men via its Pilot platform in Australia, following the acquisition of the digital health company Eucalyptus. The offering includes sexual health and cholesterol medications and is designed to increase preventative care access, leading to a 21% annual increase in subscriptions and monthly revenue per subscriber. The company noted that while international growth supported revenue, there is an expected near-term impact on gross profit margins, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, identifies clear technical weakness in Hims & Hers, with shares lingering below key moving averages and sellers dominating the session. He notes that international expansion, while positive from a strategic standpoint, has not been enough to offset broad-based selling pressure or address the adverse shift in profit margins. The expert is critical of the stock's sentiment environment, as momentum indicators stay negative and the risk of further downside prevails. He cautions that short-lived relief is unlikely unless the price can reclaim resistance levels. "With mounting profit margin pressure and a lack of convincing technical support, I see little reason to expect a sustainable reversal for HIMS in the near term."

Viktoras Karapetjanc, expert at Traders Union, concentrates on the underlying business developments and global growth opportunities driving Hims & Hers. He sees the strategic acquisition in Australia and rising international subscriptions as strong indicators of corporate health, with a robust model for future expansion. Despite near-term margin concerns, Karapetjanc believes these are temporary and outweighed by the long-term gains from growing preventative health demand. The analyst maintains that capital inflows and new markets support a constructive outlook. "International growth and subscription momentum signal that the bullish structure remains intact, setting up HIMS for further gains ahead."

Parshwa Turakhiya, analyst, observes that sentiment is neutral to mildly bearish after the recent drop, with oversold signals building intraday as sellers retain control. He points to the cluster of technical levels as a short-term battleground, where the stock fluctuates between pressure from broad selling and a foundation of longer-term support. Turakhiya finds the probability skewed toward further weakness but emphasizes the potential for a swift rebound if sentiment turns and price tests resistance around $29.32. "I see short-term setups for both nimble bulls and bears, with volatility likely to spark tradable momentum swings in the coming days."

Weak momentum prevails as shares hover above long-term technical support

Hims & Hers is trading below both the 20-day and 50-day moving averages ($30.49 and $31.99), signaling short- and medium-term selling pressure, but remains above the 200-day moving average at $28.55, which serves as longer-term support. The nearest resistance is at the Ichimoku Kijun ($29.32), with a near-term ceiling at $28.83 and a floor near the 200-day average. Momentum signals remain broadly negative: the MACD is at -0.25 with a "Sell" bias, and the ADX at 9.61 indicates a lack of a strong trend. Oscillators such as the RSI (47.49), CCI (-65.69), and Stochastic RSI (37.16) reflect mild sell or neutral-to-weak conditions, with the CCI suggesting possible oversold risk. Bull/Bear Power at -0.6 also highlights an oversold environment dominated by sellers intraday.

Earlier, analysts noted that Hims & Hers Health displayed ongoing technical weakness, though new product launches and international expansion were seen as potential growth drivers. Current analysis reinforces the downside momentum, and traders should monitor the $28.55 support level as a potential inflection point for the coming sessions.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.